Cargando…

Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan

Among treatment modalities for lung cancer, the most promising therapy is the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and gefitinib, the two first‐generation EGFR‐TKIs, exhibit significant clinical responses for patients with lung adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Chia‐Hao, Lee, Chih‐Hsin, Ko, Jen‐Chung, Chang, Lih‐Yu, Lee, Ming‐Chia, Wang, Jann‐Yuan, Yu, Chong‐Jen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504326/ https://www.ncbi.nlm.nih.gov/pubmed/28639751 http://dx.doi.org/10.1002/cam4.1121

Ejemplares similares

Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
por: Hong, Junshik, et al.
Publicado: (2010)

Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan
por: Lee, Meng-Rui, et al.
Publicado: (2017)

Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis
por: Chang, Chia-Hao, et al.
Publicado: (2015)

Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
por: Chang, Chia-Hao, et al.
Publicado: (2020)

Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib
por: Lee, Chia-Han, et al.
Publicado: (2022)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
por: Li, Ko-Jen, et al.
Publicado: (2021)

Effect of S‐1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7‐year multicenter observational cohort study in Taiwan
por: Lai, Hsiang‐Lan, et al.
Publicado: (2019)

Incidence of and Risk Factors for Acute Kidney Injury During Antituberculosis Treatment: A Prospective Cohort Study and Literature Review
por: Chang, Chia-Hao, et al.
Publicado: (2023)

The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nation‐wide cancer registry‐based study from Taiwan
por: Chang, Jeffrey S., et al.
Publicado: (2018)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
por: Liang, Sheng-Kai, et al.
Publicado: (2021)

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
por: Emery, Ivette F, et al.
Publicado: (2009)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Acute biliary events during anti-tuberculosis treatment: hospital case series and a nationwide cohort study
por: Chang, Lih-Yu, et al.
Publicado: (2018)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Case of Proteinuria, Worsening Hypertension, and Glomerular Endotheliosis With Erlotinib and Gefitinib
por: Latcha, Sheron, et al.
Publicado: (2018)

Deep learning with test-time augmentation for radial endobronchial ultrasound image differentiation: a multicentre verification study
por: Yu, Kai-Lun, et al.
Publicado: (2023)

Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report
por: Ohara, Sayaka, et al.
Publicado: (2014)

Sero-Diagnosis of Mycobacterium avium Complex Lung Disease Using Serum Immunoglobulin A Antibody against Glycopeptidolipid Antigen in Taiwan
por: Shu, Chin-Chung, et al.
Publicado: (2013)

A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
por: Thomas, Preenumol, et al.
Publicado: (2019)

Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study
por: Lee, Meng-Rui, et al.
Publicado: (2019)

Strategies for supplying face masks to the population of Taiwan during the COVID-19 pandemic
por: Liu, Chin-Mei, et al.
Publicado: (2021)

Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
por: Jung, Minkyu, et al.
Publicado: (2012)

Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population
por: Chang, Chia-Hao, et al.
Publicado: (2014)

Performance of Nucleic Acid Amplification Tests in Patients with Presumptive Pulmonary Tuberculosis in Taiwan
por: Huang, Wei-Chang, et al.
Publicado: (2022)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
por: Lin, Shu-Yung, et al.
Publicado: (2018)

Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2022)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
por: Wong, Matthew K., et al.
Publicado: (2009)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

One-Year Healthcare Utilization and Expenditures Among Patients with Clinically Significant Mitral Regurgitation in Taiwan
por: Chung, Ching-Hu, et al.
Publicado: (2022)

Predicting results of mycobacterial culture on sputum smear reversion after anti-tuberculous treatment: a case control study
por: Shu, Chin-Chung, et al.
Publicado: (2010)

EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis
por: You, Joyce H. S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_13d5ojjkmr7kdhf1pcgmlncd2j